🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Antibody-drug Conjugates

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836Phase 118 sites📍 Boston📍 St Louis📍 Hackensack BeOne Medicines · Tests: BG-C0979, Tislelizumab JSKN022 in Subjects With Advanced Malignant Solid Tumors NCT07292402Phase 11 site📍 Guangzhou Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN022 A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928Phase 17 sites📍 Duarte📍 La Jolla📍 Aurora Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: bulumtatug fuvedotin, bulumtatug fuvedotin Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors NCT07360314Phase 19 sites📍 New Haven📍 Huntersville📍 Galveston EMD Serono Research & Development Institute, Inc. · Tests: M7437, M7437 IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites📍 Newport Beach📍 Boston📍 Nashville Iksuda Therapeutics Ltd. · Tests: IKS014 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia NCT07109219Phase 1, Phase 227 sites📍 Duarte📍 Jacksonville📍 Chicago AstraZeneca · Tests: AZD4512 monotherapy A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189Phase 3111 sites📍 Huntsville📍 Tucson📍 Duarte Corbus Pharmaceuticals Inc. · Tests: CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] NCT07099898Phase 3144 sites📍 Los Angeles📍 Miami📍 Plantation GlaxoSmithKline · Tests: Risvutatug rezetecan (Ris-Rez), Topotecan A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer NCT05754853Phase 31 site📍 Beijing Shanghai Miracogen Inc. · Tests: MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injecti… A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases NCT07268053EARLY Phase 11 site📍 Phoenix Nader Sanai · Tests: Risvutatug rezetecan AMT-676 in Patients With Advanced Solid Tumors NCT06400485EARLY Phase 113 sites📍 Huntersville📍 Philadelphia📍 San Antonio Multitude Therapeutics Inc. · Tests: AMT-676 Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer NCT06877416n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: Non-intervention research EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors NCT06525298Phase 1, Phase 21 site📍 Houston Eisbach Bio GmbH · Tests: EIS-12656, Olaparib, Trastuzumab deruxtecan Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336Phase 3320 sites📍 Tucson📍 La Jolla📍 Los Angeles AstraZeneca · Tests: Puxitatug Samrotecan, Doxorubicin, Paclitaxel Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027n/a3 sites📍 San Francisco📍 The Bronx📍 Durham University of California, San Francisco · Tests: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168Phase 1, Phase 261 sites📍 Sarasota📍 Sarasota📍 Locust Grove Daiichi Sankyo · Tests: DS-3939a DEC003M in Prostate Cancer NCT07657806Phase 17 sites📍 Beijing📍 Suzhou📍 Chengdu Hangzhou DAC Biotechnology Co., Ltd. · Tests: DEC003M TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd NCT06533826Phase 211 sites📍 Birmingham📍 San Francisco📍 New Haven Ana C Garrido-Castro, MD · Tests: Trastuzumab Deruxtecan, Datopotamab Deruxtecan A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07408063Phase 21 site📍 Toronto University Health Network, Toronto · Tests: GSK5764227, Dostarlimab A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN NCT05751512Phase 31 site📍 Shanghai Lepu Biopharma Co., Ltd. · Tests: MRG003, Cetuximab injection, Methotrexate Injection Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab, Trastuzumab Rezetecan A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy NCT07869836Phase 32 sites📍 Macon📍 Macon SystImmune Inc. · Tests: T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma NCT04822337Phase 1, Phase 22 sites📍 Charlotte📍 Winston-Salem Wake Forest University Health Sciences · Tests: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin SMP-656 for HER2-Positive Advanced Breast Cancer NCT07726342Phase 215 sites📍 Hefei📍 Beijing📍 Beijing Chengdu SciMount Pharmatech Co., Ltd. · Tests: SMP-656 Injection, SMP-656 Injection A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors NCT07093970Phase 1, Phase 22 sites📍 Beijing📍 Shanghai Lepu Biopharma Co., Ltd. · Tests: MRG006A A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07545356Phase 13 sites📍 Sydney📍 Wollongong📍 Brisbane Kivu Bioscience Inc. · Tests: KIVU-305
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy